community health systems inc. - CYH
CYH
Close Chg Chg %
3.74 -0.07 -1.74%
Closed Market
3.67
-0.07 (1.74%)
Volume: 2.85M
Last Updated:
Nov 22, 2024, 3:59 PM EDT
Company Overview: community health systems inc. - CYH
CYH Key Data
| Open $3.62 | Day Range 3.48 - 3.68 |
| 52 Week Range 2.31 - 6.28 | Market Cap $521.06M |
| Shares Outstanding 138.95M | Public Float 118.97M |
| Beta 1.60 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.01 |
| Yield 0.00% | Dividend $3.38 |
| EX-DIVIDEND DATE May 2, 2016 | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.36M |
CYH Performance
| 1 Week | -4.95% | ||
| 1 Month | -8.52% | ||
| 3 Months | -27.87% | ||
| 1 Year | 27.18% | ||
| 5 Years | 15.51% |
CYH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About community health systems inc. - CYH
Community Health Systems, Inc. engages in the provision of general and specialized healthcare services and outpatient services. The company was founded in March 1985 and is headquartered in Franklin, TN.
CYH At a Glance
Community Health Systems, Inc.
4000 Meridian Boulevard
Franklin, Tennessee 37067
| Phone | 1-615-465-7000 | Revenue | 12.49B | |
| Industry | Hospital/Nursing Management | Net Income | -133,000,000.00 | |
| Sector | Health Services | 2023 Sales Growth | 2.285% | |
| Fiscal Year-end | 12 / 2024 | Employees | 61,000 | |
| View SEC Filings |
CYH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.033 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 1.944 |
| Enterprise Value to EBITDA | 9.28 |
| Enterprise Value to Sales | 1.05 |
| Total Debt to Enterprise Value | 0.928 |
CYH Efficiency
| Revenue/Employee | 204,754.098 |
| Income Per Employee | -2,180.328 |
| Receivables Turnover | 5.29 |
| Total Asset Turnover | 0.858 |
CYH Liquidity
| Current Ratio | 1.498 |
| Quick Ratio | 1.345 |
| Cash Ratio | 0.018 |
CYH Profitability
| Gross Margin | 7.27 |
| Operating Margin | 7.27 |
| Pretax Margin | 1.657 |
| Net Margin | -1.065 |
| Return on Assets | -0.913 |
| Return on Equity | N/A |
| Return on Total Capital | -1.234 |
| Return on Invested Capital | -1.238 |
CYH Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 112.91 |
| Total Debt to Total Assets | 84.22 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 111.566 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Community Health Systems Inc. - CYH
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 11.79B | 12.37B | 12.21B | 12.49B | |
Sales Growth
| -10.76% | +4.91% | -1.27% | +2.28% | |
Cost of Goods Sold (COGS) incl D&A
| 11.21B | 11.09B | 11.48B | 11.58B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 558.00M | 540.00M | 534.00M | 505.00M | |
Depreciation
| 434.00M | 431.00M | 448.00M | 420.00M | |
Amortization of Intangibles
| 124.00M | 109.00M | 86.00M | 85.00M | |
COGS Growth
| -8.90% | -1.12% | +3.58% | +0.86% | |
Gross Income
| 577.00M | 1.28B | 728.00M | 908.00M | |
Gross Income Growth
| -36.10% | +122.18% | -43.21% | +24.73% | |
Gross Profit Margin
| +4.89% | +10.37% | +5.96% | +7.27% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| - | - | - | - | - |
Research & Development
| - | - | - | - | - |
Other SG&A
| - | - | - | - | - |
SGA Growth
| - | - | - | - | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (866.00M) | (41.00M) | (346.00M) | (34.00M) | |
EBIT after Unusual Expense
| 1.44B | 1.32B | 1.07B | 942.00M | |
Non Operating Income/Expense
| 15.00M | 64.00M | 135.00M | 97.00M | |
Non-Operating Interest Income
| 3.00M | 3.00M | 2.00M | 2.00M | |
Equity in Earnings of Affiliates
| 10.00M | 22.00M | 14.00M | 8.00M | |
Interest Expense
| 1.04B | 888.00M | 860.00M | 832.00M | |
Interest Expense Growth
| -1.05% | -14.29% | -3.15% | -3.26% | |
Gross Interest Expense
| 1.05B | 901.00M | 869.00M | 845.00M | |
Interest Capitalized
| 15.00M | 13.00M | 9.00M | 13.00M | |
Pretax Income
| 422.00M | 499.00M | 349.00M | 207.00M | |
Pretax Income Growth
| +198.14% | +18.25% | -30.06% | -40.69% | |
Pretax Margin
| +3.58% | +4.03% | +2.86% | +1.66% | |
Income Tax
| (185.00M) | 131.00M | 170.00M | 191.00M | |
Income Tax - Current - Domestic
| 2.00M | (40.00M) | 5.00M | 156.00M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (187.00M) | 171.00M | 165.00M | 35.00M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 10.00M | 22.00M | 14.00M | 8.00M | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 607.00M | 368.00M | 179.00M | 16.00M | |
Minority Interest Expense
| 96.00M | 138.00M | 133.00M | 149.00M | |
Net Income
| 511.00M | 230.00M | 46.00M | (133.00M) | |
Net Income Growth
| +175.70% | -54.99% | -80.00% | -389.13% | |
Net Margin Growth
| +4.33% | +1.86% | +0.38% | -1.06% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 511.00M | 230.00M | 46.00M | (133.00M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 511.00M | 230.00M | 46.00M | (133.00M) | |
EPS (Basic)
| 4.4246 | 1.8145 | 0.3571 | -1.0196 | |
EPS (Basic) Growth
| +174.56% | -58.99% | -80.32% | -385.52% | |
Basic Shares Outstanding
| 115.49M | 126.75M | 128.81M | 130.45M | |
EPS (Diluted)
| 4.3846 | 1.7611 | 0.3537 | -1.0196 | |
EPS (Diluted) Growth
| +173.88% | -59.83% | -79.92% | -388.27% | |
Diluted Shares Outstanding
| 116.54M | 130.60M | 130.06M | 130.45M | |
EBITDA
| 1.14B | 1.82B | 1.26B | 1.41B | |
EBITDA Growth
| -24.88% | +60.53% | -30.74% | +11.97% | |
EBITDA Margin
| +9.63% | +14.73% | +10.33% | +11.31% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 5.075 | |
| Number of Ratings | 9 | Current Quarters Estimate | 0.095 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -0.506 | |
| Last Quarter’s Earnings | -0.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.39 | Next Fiscal Year Estimate | 0.205 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 6 | 8 | 8 |
| Mean Estimate | 0.09 | 0.00 | -0.51 | 0.21 |
| High Estimates | 0.22 | 0.12 | -0.30 | 0.50 |
| Low Estimate | 0.01 | -0.16 | -0.59 | -0.32 |
| Coefficient of Variance | 86.44 | 3,570.96 | -21.06 | 159.22 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 5 | 6 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 0 | 0 |
| MEAN | Hold | Overweight | Overweight |
SEC Filings for Community Health Systems Inc. - CYH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Community Health Systems Inc. - CYH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 4, 2024 | Susan W. Brooks Director | 21,544 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 4, 2024 | Susan W. Brooks Director | 5,894 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 4, 2024 | Fawn D Lopez Director | 62,718 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2024 | Charles J. Cova Regional President | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | James S. Ely Director | 19,512 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | John A. Clerico Director | 62,718 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | John A. Clerico Director | 19,512 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | John A. Clerico Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | John A. Clerico Director | 281,612 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | John A. Clerico Director | 271,856 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | John A. Clerico Director | 265,962 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | James S. Ely Director | 62,718 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Michael Dinkins Director | 143,014 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | James S. Ely Director | 322,843 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | James S. Ely Director | 313,087 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Michael Dinkins Director | 62,718 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2024 | Michael Dinkins Director | 19,512 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Michael Dinkins Director | 5,894 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Michael Dinkins Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2024 | Michael Dinkins Director | 158,664 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |